Myeloablative intravenous busulfan-containing regimens for allo-HSCT in AML or MDS patients over 54 years old: combined results of three phase II studies.
Uchida N, Matsumoto K, Sakura T, Hidaka M, Miyamoto T, Eto T, Maeda Y, Murayama T, Fujishima N, Yoshimoto G, Morita K, Kishimoto J, Teshima T, Taniguchi S, Yamashita T, Mori SI, Akashi K, Harada M; Japan Study Group for Cell Therapy, Transplantation (JSCT).
Uchida N, et al. Among authors: mori si.
Int J Hematol. 2020 Oct;112(4):510-523. doi: 10.1007/s12185-020-02941-7. Epub 2020 Jul 12.
Int J Hematol. 2020.
PMID: 32656637